Sarepta Therapeutics Faces Lawsuit and Investor Investigation
A class action lawsuit was filed against Sarepta Therapeutics alleging that the company and its officers made false and misleading statements about the safety and efficacy of its gene therapy drug Elevidys for Duchenne muscular dystrophy, omitting critical safety concerns that led to FDA investigations and a significant stock decline.